Intervention Review

You have free access to this content

Calcium antagonists as an add-on therapy for drug-resistant epilepsy

  1. Mohammad Hasan*,
  2. Jennifer Pulman,
  3. Anthony G Marson

Editorial Group: Cochrane Epilepsy Group

Published Online: 28 MAR 2013

Assessed as up-to-date: 27 FEB 2013

DOI: 10.1002/14651858.CD002750.pub2


How to Cite

Hasan M, Pulman J, Marson AG. Calcium antagonists as an add-on therapy for drug-resistant epilepsy. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD002750. DOI: 10.1002/14651858.CD002750.pub2.

Author Information

  1. Institute of Translational Medicine, University of Liverpool, Department of Molecular and Clinical Pharmacology, Liverpool, UK

*Mohammad Hasan, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Clinical Sciences Centre, University Hospital Aintree, Lower Lane, Fazakerley, Liverpool, L9 7AL, UK. dr.mohammadhasan@gmail.com. M.Hasan@liverpool.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 28 MAR 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Alving 1989 {published data only}
  • Alving J, Kristensen O, Tsiropoulos I, Mondrup K. Double-blind placebo-controlled evaluation of flunarizine as adjunct therapy in epilepsy with complex partial seizures. Acta Neurologica Scandinavica 1989;79:128-32.
Battaglia 1991 {published data only}
  • Battaglia A, Ferrari AR, Guerrini R. Double-blind placebo-controlled trial of flunarizine as add-on therapy in refractory childhood epilepsy. Brain and Development 1991;13(4):217-22.
Fröscher 1988 {published data only}
  • Froscher W, Bulau P, Burr W, Penin H, Rao ML, de Beukelaar F. Double-blind placebo-controlled trial with flunarizine in therapy-resistant epileptic patients. Clinical Neuropharmacology 1988;11(3):232-40.
Keene 1989 {published data only}
  • Keene D, Whiting S, Humphreys P, Jacob P. Flunarizine as a supplementary medication in refractory childhood epilepsy: a double-blind crossover study. Canadian Journal of Neurological Sciences 1989;16(2):191-3.
Larkin 1991 {published data only}
  • Larkin JG, McKee PJW, Blacklaw J, Thompson GG, Morgan IC, Brodie MJ. Nimodipine in refractory epilepsy: a placebo-controlled, add-on study. Epilepsy Research 1991;9:71-7.
Larkin 1992 {published data only}
Moglia 1986 {published data only}
  • Moglia A, Bergamasco B, Di Perri R, Mancia D. Flunarizine as add-on therapy in epilepsy: crossover study versus placebo. Functional Neurology 1986;1(4):547-50.
Overweg 1984 {published data only}
Pelliccia 1993 {published data only}
  • Pelliccia A, Sciarretta A, Monticelli M, Porro G, Matricardi M. Nimodipine in drug-resistant childhood epilepsy: a double-blind, placebo-controlled trial [Impiego della nimodipina nelle epilessia farmacoresistente: studio in doppio cieco placebo-controllato]. Bolletino Lega Italiana Contro L'Epilessia 1993;82/83:153-4.
Pledger 1994 {published data only}
  • Pledger GW, Sackellares JC, Treiman DM, Pellock JM, Wright FS, Mikati M, et al. Flunarizine for treatment of partial seizures: results of a concentration-controlled trial. Neurology 1994;44:1830-6.
Starreveld 1989 {published data only}
  • Starreveld E, De Beukelaar F, Wilson AF, McLean DR, Findlay HP. Double-blind cross-over placebo controlled study of flunarizine in patients with therapy resistant epilepsy. Canadian Journal of Neurological Sciences 1989;16:187-90.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Binnie 1985 {published data only}
Cavazzuti 1986 {published data only}
  • Cavazzuti GB, Galli V, Benatti A. The use of flunarizine in pediatric epilepsy. Functional Neurology 1986;1(4):551-4.
Handforth 1995 {published data only}
  • Handforth A,  Mai T,  Treiman DM. Rising dose study of safety and tolerance of flunarizine. European Journal of Clinical Pharmacology 1995;49:91-4.
Malashkhia 1996 {published data only}
  • Malashkhia VY, Nadareishvili ZG, Malashkhia YA. Add-on therapy with nimodipine in intractable epilepsy of childhood. Journal of Child Neurology 1996;11(6):500-1.
Meyer 1995 {published data only}
  • Cascino GD, Meyer FB, Sharbrough FW, Ivnik RJ, Hirschorn KA, So EL, et al. Nimodipine for intractable seizures: a double-blind placebo-controlled crossover study. Epilepsia 1992;33 Suppl 3:119.
  • Meyer FB, Cascino GD, Whisnant JP, Sharbrough FW, Ivnik RJ, Gorman DA, et al. Nimodipine as an add-on therapy for intractable epilepsy. Mayo Clinic Proceedings 1995;70:623-7.
Sasso 1993 {published data only}
  • Sasso E, Delsoldato S, Mancia D. Nimodipine as adjunctive therapy in refractory epilepsy [Effetto della nimodipina nelle epilessie farmacoresistenti]. Bolletino Lega Italiana Contro L'Epilessia 1993;82/83:155-6.
Treiman 1993 {published data only}

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Andrade 2012 {unpublished data only}
  • Verapamil study in refractory epilepsy. http://clinicaltrials.gov/ct2/show/NCT01126307.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Bonnett 2012
  • Bonnett L,  Smith CT,  Smith D,  Williamson P,  Chadwick D,  Marson AG. Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial. Lancet Neurology 2012;11(4):331-40. [DOI: 10.1016/S1474-4422(12)70018-2]
Higgins 2010
  • Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Handbook for Systematic Reviews of Interventions. West Sussex: John Wiley & Sons Ltd, 2010.
Jouvenceau 2001
Nunes 2012
  • Nunes VD,  Sawyer L,  Neilson J,  Sarri G,  Cross JH. Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ 2012;344:e281.
Reynolds 1993
  • Reynolds J. Martindale: The extra pharmacopoeia. 30th Edition. London: Pharmaceutical Press, 1993.
Smith 2005
Summers 2004
Triggle 2007

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Chaisewikul 2001
  • Chaisewikul R, Baillie N, Marson AG. Calcium antagonists as an add-on therapy for drug-resistant epilepsy. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD002750]